SPOTLIGHT -
Dr. Dimopoulos on the Goal of the ASPEN Trial in Waldenström Macroglobulinemia
Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.
Read More
Dr. Dimopoulos on the Utility of Zanubrutinib in Waldenström Macroglobulinemia
Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.
Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.
Dr. Dimopoulos on the Evolution of Selinexor in Multiple Myeloma
Meletios A. Dimopoulos, MD, discusses the evolution of selinexor in multiple myeloma.
Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC
